Form 4: Phathom Pharmaceuticals Director Asit Parikh Receives Significant Equity Grant

Phathom Pharmaceuticals, Inc. Director Asit Parikh was granted 10,500 Restricted Stock Units and 17,500 stock options as part of the company's Non-Employee Director Compensation Program.

Summary

• Asit Parikh, a Director of Phathom Pharmaceuticals, Inc. (PHAT), acquired 10,500 shares of Common Stock in the form of Restricted Stock Units (RSUs) on June 3, 2025.
• These RSUs were granted pursuant to the Issuer's Non-Employee Director Compensation Program and represent a contingent right to receive one share of common stock per RSU.
• The RSUs are set to vest 100% on the first anniversary of the grant date (June 3, 2026) or the next annual meeting of stockholders, whichever occurs first, contingent on Mr. Parikh's continued service on the Board.
• Additionally, Mr. Parikh was granted 17,500 stock options on June 3, 2025, with an exercise price of $4.95 per share.
• These stock options also vest on the first anniversary of the grant date (June 3, 2026) or the next annual meeting, subject to his continued service.
• The stock options have an expiration date of June 2, 2035.
• Following these transactions, Mr. Parikh beneficially owns 113,500 shares of Common Stock and 17,500 derivative securities (stock options).

Sentiment

Score: 6

Explanation: The document reports a routine equity grant to a director, which is a positive for aligning management and shareholder interests, but does not contain information that would significantly alter the company's financial outlook or operations.

Positives

• The equity grants align the interests of Director Asit Parikh with those of the shareholders, as his compensation is tied to the company's stock performance.
• The grants are part of a pre-established Non-Employee Director Compensation Program, indicating a structured approach to governance and incentives.

Future Outlook

The vesting schedule for the granted RSUs and stock options indicates an expectation for Director Asit Parikh to continue his service on the Board of Directors for at least one year or until the next annual meeting of stockholders.

Industry Context

This filing reflects a standard practice in corporate governance where non-employee directors receive a portion of their compensation in the form of equity, such as Restricted Stock Units and stock options. This method is widely used across various industries, particularly in the biotechnology and pharmaceutical sectors, to align the interests of directors with long-term shareholder value.

Comparison to Industry Standards

• The grant of equity (RSUs and stock options) to non-employee directors is a common and widely accepted practice in the U.S. public company landscape, including within the pharmaceutical industry.
• The vesting schedule, typically tied to continued service over one year or until the next annual meeting, is standard for such compensation programs, similar to practices observed at companies like Biogen Inc. or Vertex Pharmaceuticals Incorporated, which also utilize equity-based compensation to incentivize and retain board members.

Related Party Transactions

• The transaction involves an equity grant to a director, Asit Parikh, as part of the Issuer's Non-Employee Director Compensation Program. This is a standard compensation arrangement for a related party (director).

Stakeholder Impact

• Shareholders: The equity grant aligns the director's financial interests with the long-term performance of the company's stock, potentially benefiting shareholders through improved governance and strategic decisions.
• Employees: No direct impact on employees is indicated by this specific filing.

Next Steps

• The RSUs and stock options are expected to vest on the first anniversary of the grant date (June 3, 2026) or the next annual meeting of stockholders, subject to continued service.

Key Dates

Keywords

Phathom Pharmaceuticals, PHAT, Asit Parikh, Director Compensation, Restricted Stock Units, RSU, Stock Options, Equity Grant, Insider Transaction, SEC Form 4